Identification of Prognostic Markers of N6-Methylandenosine-Related Noncoding RNAs in Non-Small-Cell Lung Cancer

被引:2
|
作者
Zhang, Zexin [1 ]
Li, Jing [2 ]
Lu, Ke [1 ]
Wu, Wenfeng [3 ]
Huang, Ziyi [3 ]
Zhang, Chi [1 ]
Guo, Wei [1 ]
Li, Jiayin [4 ]
Lin, Lizhu [4 ,5 ]
机构
[1] Guangzhou Univ Tradit Chinese Med, Clin Med Coll 1, Guangzhou, Peoples R China
[2] Hunan Univ Tradit Chinese Med, Affiliated Hosp 1, Changsha, Peoples R China
[3] Guangzhou Univ Tradit Chinese Med, Clin Med Coll 2, Guangzhou, Peoples R China
[4] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China
[5] China Ctr Evidence Based Tradit Chinese Med, Canc Project Team, Guangzhou, Peoples R China
关键词
ONCOGENIC ROLE; YAP ACTIVITY; EXPRESSION;
D O I
10.1155/2022/3657349
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Non-small-cell lung cancer (NSCLC) is a major type of lung carcinoma that threatens the health and life of humans worldwide. We aimed to establish an n6-methyladenosine (m6A)-relevant ncRNA model to effectively evaluate the outcome of patients. Methods. m6A-Related ncRNAs (lncRNA/miRNA) were acquired from the UCSC Xena database. Pearson's correlation analysis among 21 m6A regulatory factors and ncRNAs were implemented to explore m6A-relevant ncRNAs. Weighted gene co-xpression network analysis (WGCNA) identified hub modules of gene associated with prognosis of NSCLC patients. Univariate Cox regression analysis identified 80 m6A-related ncRNAs. Least absolute shrinkage and selector operation (LASSO) filtered out redundant factors and established a risk score model (m6A-NSCLC) in the TCGA training data set. Validation of prognostic ability was performed using testing data sets from the TCGA database. We also conducted a correlation analysis among the risk score and different clinical traits. Both univariate and multivariate Cox analyses were combined to verify prognostic factors which have independent value, and a nomogram on the basis of m6A-NSCLC risk scores and clinical traits was constructed to assess the prognosis of patients. In addition, we screened differentially expressed genes (DEGs) based on different risk scores and performed enrichment analysis. Finally, 21 m6A regulators were detected to be differentially expressed between two risk groups. Results. An m6A-NSCLC risk model with 18 ncRNAs was constructed. By comparison with low-risk patients, high-risk score patients had poor prognosis. Th distribution of risk score in the tumor size and extent (T), number of near lymph nodes (N), clinical stage, sex, and tumor types was significantly different.The risk score could act as an independent prognostic factor with the nomogram assessing overall survival in NSCLC. DEGs inherent to cell movement and immune regulation were involved in NSCLC development. Furthermore, 18 of 21 m6A regulators were differentially expressed, implying their correlation to survival prognosis. Conclusion. The m6A-NSCLC could be effectively utilized for evaluation of prognosis of patients.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Long Non-coding RNAs and Their Roles in Non-small-cell Lung Cancer
    Wei, Ming-Ming
    Zhou, Guang-Biao
    GENOMICS PROTEOMICS & BIOINFORMATICS, 2016, 14 (05) : 280 - 288
  • [32] Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications
    Osaki T.
    Oyama T.
    Inoue M.
    Gu C.-D.
    Kodate M.
    Aikawa M.
    So T.
    Mizukami M.
    Mitsudomi T.
    Yasumoto K.
    The Japanese Journal of Thoracic and Cardiovascular Surgery, 2001, 49 (9): : 545 - 551
  • [33] Construction of a prognostic signature of autophagy-related lncRNAs in non-small-cell lung cancer
    Zhang, Xinyang
    Cao, Yu
    Chen, Li
    BMC CANCER, 2021, 21 (01)
  • [34] Survival and Prognostic Factor in Pathological N1 Non-Small-Cell Lung Cancer
    Yamamoto, Taketsugu
    Maehara, Takamitsu
    Masuda, Munetaka
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S670 - S670
  • [35] Biologic markers for targeted therapy in non-small-cell lung cancer
    Nature Clinical Practice Oncology, 2005, 2 (8): : 381 - 381
  • [36] Molecular markers of various stages of non-small-cell lung cancer
    Zborovskaya, IB
    Tatosyan, AG
    MOLECULAR BIOLOGY, 2004, 38 (02) : 155 - 164
  • [37] Molecular Markers of Various Stages of Non-Small-Cell Lung Cancer
    I. B. Zborovskaya
    A. G. Tatosyan
    Molecular Biology, 2004, 38 : 155 - 164
  • [38] Evaluating the expression of tumorigenic long noncoding RNAs in circulating exosomes isolated from non-small-cell lung cancer patients
    Shi, Zhenshan
    Huang, Kaicheng
    Li, Zheng
    Niu, Yanli
    Jiang, Lihao
    BIOMARKERS IN MEDICINE, 2022, 16 (04) : 241 - 251
  • [39] A practical prognostic index for inoperable non-small-cell lung cancer
    Tuija Wigren
    Hanna Oksanen
    Pirkko Kellokumpu-Lehtinen
    Journal of Cancer Research and Clinical Oncology, 1997, 123 : 259 - 266
  • [40] Is there a need for new prognostic factors in non-small-cell lung cancer?
    Pirker, R
    ONKOLOGIE, 1998, 21 (03): : 248 - 248